Drug Profile
CYC 116
Alternative Names: CYC-116Latest Information Update: 21 Apr 2016
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 16 Apr 2008 Preclinical pharmacodynamics data in Haematological malignancies presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
- 27 Nov 2007 Interim efficacy and safety data from a phase I trial in solid tumours released by Cyclacel
- 30 Jun 2007 Phase-I clinical trials in Solid tumours in USA (PO)